Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLV9 | ISIN: FR0013233012 | Ticker-Symbol: 6IV
Tradegate
21.11.24
11:07 Uhr
2,530 Euro
-0,060
-2,32 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INVENTIVA SA Chart 1 Jahr
5-Tage-Chart
INVENTIVA SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,4102,42012:58
2,4002,43512:45

Aktuelle News zur INVENTIVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INVENTIVA Aktie jetzt für 0€ handeln
MiINVENTIVA: Combined General Meeting of December 11, 2024 - Availability of the preparatory documents192Daix (France), Long Island City (New York, United States), November 20, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
► Artikel lesen
MiINVENTIVA: Statement of total voting rights and shares forming the company's share capital as of November 4, 2024186Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com Date Number of Shares Outstanding Total voting...
► Artikel lesen
FrINVENTIVA: Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting late-breaker session259Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...
► Artikel lesen
FrInventiva S.A. - 6-K, Report of foreign issuer-
30.10.Inventiva S.A. - 6-K, Report of foreign issuer-
30.10.INVENTIVA: Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH244The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on...
► Artikel lesen
21.10.INVENTIVA: Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024219Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
16.10.H.C. Wainwright senkt Kursziel für Inventiva-Aktien aufgrund von Kapitalzufuhr und Führungswechsel vor wichtigen Studien6
16.10.H.C. Wainwright cuts Inventiva shares target, citing cash infusion and leadership changes ahead of key trials3
15.10.Inventiva S.A. - 6-K, Report of foreign issuer1
14.10.Inventiva Aktie: Finanzspritze sichert klinische Studie431Inventiva, ein biopharmazeutisches Unternehmen, hat eine bedeutende Finanzierungsrunde abgeschlossen. Die Firma sicherte sich zunächst 94,1 Millionen Euro, mit der Option auf insgesamt bis zu 348 Millionen...
► Artikel lesen
14.10.INVENTIVA: Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants260Daix (France), Long Island City (New York, United States), October 14, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
14.10.Stifel reiterates Buy rating on Inventiva stock, cites financing deal5
14.10.Inventiva secures up to $380m for MASH treatment lanifibranor6
14.10.Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?4
14.10.Inventiva Shares Surge In Pre-market After Securing Finance To Advance NATiV3 Phase 3 MASH Study5
14.10.HotStocks USA: +53 % bei Inventiva, + 51 % bei Longboard Pharmaceuticals7
14.10.Inventiva secures financing of up to €348M to advance the Nativ3 phase 3 MASH study8
14.10.INVENTIVA: Inventiva announces Filing of 2024 Half-Year Report - Conditions for Accessing or Consulting the Report217Daix (France), Long Island City (New York, United States), October 14, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
14.10.INVENTIVA: Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study245Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million...
► Artikel lesen
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1